Abstract:Osteoclastic inhibition using antiresorptive bisphosphonates and osteogenic promotion using antisclerostin agents represent two distinct osteoporosis treatments in clinical practice, each individual treatment suffers from unsatisfactory therapeutic efficacy due to its indirect intervention in osteoclasis and promotion of osteogenesis simultaneously. Although this issue is anticipated to be resolved by drug synergism, a tempting carrier-free dual-medication nanoassembly remains elusive. Herein, we prepare such a nanoassembly made of antiresorptive alendronate (ALN) crystal and antisclerostin polyaptamer (Apt) via a nucleic acid-driven crystallization method. This nanoparticle can protect Apt from rapid nuclease degradation, avoid the high cytotoxicity of free ALN, and effectively concentrate in the cancellous bone by virtue of the bone-binding ability of DNA and ALN. More importantly, the acid microenvironment of cancellous bone triggers the disassociation of nanoparticles for sustained drug release, from which ALN inhibits the osteoclast-mediated bone resorption while Apt promotes osteogenic differentiation. Our work represents a pioneering demonstration of nucleic acid-driven crystallization of a bisphosphonate into a tempting carrier-free dual-medication nanoassembly. This inaugural advancement augments the antiosteoporosis efficacy through direct inhibition of osteoclasis and promotion of osteogenesis simultaneously and establishes a paradigm for profound understanding of the underlying synergistic antiosteoporosis mechanism of antiresorptive and antisclerostin components. It is envisioned that this study provides a highly generalizable strategy applicable to the tailoring of a diverse array of DNA-inorganic nanocomposites for targeted regulation of intricate pathological niches.

Inherent anchorages in UiO-66 nanoparticles for efficient capture of alendronate and its mediated release.

Preparation and Biological Characterization of Hollow Magnetic Fe3O4@C Nanoparticles As Drug Carriers with High Drug Loading Capability, Ph-Control Drug Release and MRI Properties

Calcium doped mesoporous silica nanoparticles as efficient alendronate delivery vehicles

Assembled Fe3O4 nanoparticles on ZnAl LDH nanosheets as a biocompatible drug delivery vehicle for pH-responsive drug release and enhanced anticancer activity

Biomimetic mineralization of nanocrystalline hydroxyapatites on aminated modified polylactic acid microspheres to develop a novel drug delivery system for alendronate

Synthesis of Novel Core–shell Structural AuNR@MCM-41 for Infrared Light-Driven Release of Drug

PEGylated chitosan decorated UiO-66 nanoscale metal–organic frameworks as promising carriers for drug delivery

Development of pH-Sensitive Alendronate-Decorated Silk Fibroin/ Alginate Nanoparticles for Active Targeting of Doxorubicin to Bone Cancers

Alendronate-functionalized polymeric micelles target icaritin to bone for mitigating osteoporosis in a rat model

Strengthening the potential of biomineralized microspheres in enhancing osteogenesis via incorporating alendronate

Dual-crosslinked networks of superior stretchability and toughness polyacrylamide-carboxymethylcellulose hydrogel for delivery of alendronate

UiO-66(Zr) as drug delivery system for non-steroidal anti-inflammatory drugs

Alendronate Conjugated Nanoparticles for Calcification Targeting

Polyaptamer-Driven Crystallization of Alendronate for Synergistic Osteoporosis Treatment through Osteoclastic Inhibition and Osteogenic Promotion

A novel high doxorubicin-loaded Fe3O4@void@ZnO nanocomposite: pH-controlled drug release and targeted antitumor activity

ZnO-incorporated alginate assemblies: Tunable pH-responsiveness and improved drug delivery for cancer therapy

Efficient internalization of nano architectured 177Lu-hyaluronic acid@ zirconium-based metal-organic framework for the treatment of neuroblastoma: Unravelling toxicity, stability, radiolabelling and bio-distribution

Alginate-Coated Fe3O4 Hollow Microspheres for Drug Delivery

A Preloaded Amorphous Calcium Carbonate/Doxorubicin@Silica Nanoreactor for Ph‐responsive Delivery of an Anticancer Drug

Folic Acid-functionalized Zr-based Metal-Organic Frameworks as Drug Carriers for Active Tumor-Targeted.

Folic Acid Functionalized Zirconium-Based Metal-Organic Frameworks as Drug Carriers for Active Tumor-Targeted Drug Delivery.